Status: Recruiting
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
Participants needed: 124
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Hannah Choe, MDUpdated: Dec 24, 2025Locations: 1
Eligibility criteria
Age 18.0 years or older at the time of enrollment [+18]
Prior allogeneic transplant [+19]